RxDoctor Payments Data

Ugochukwu Okereke, MD

Internal Medicine · Sumter, SCNPI 1942227749

Payments from drug & device makers

$535in general payments, 2019–2025

Across 38 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$142
  • GSK$128
  • AstraZeneca$71
  • Sanofi-aventis U.S. LLC$44
  • Novartis$43
  • Merck$37
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$52498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)8$142
GSK11$128
AstraZeneca5$71
Sanofi-aventis U.S. LLC3$44
Novartis3$43
Merck3$37
Boehringer Ingelheim2$30
Novo Nordisk2$26
Johnson & Johnson1$14

How this compares

$535 in reported general payments places this provider in the 55th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$182,779
Medicare patients
213
Services billed
4,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin392$435,996
OzempicSemaglutide206$249,137
TrulicityDulaglutide184$213,790
EliquisApixaban211$191,528
JanuviaSitagliptin Phosphate158$171,938
Breo ElliptaFluticasone/Vilanterol114$66,466
JanumetSitagliptin Phos/Metformin Hcl68$59,140
EntrestoSacubitril/Valsartan46$51,033
FarxigaDapagliflozin Propanediol34$40,348
TradjentaLinagliptin28$31,605
Tresiba Flextouch U-100Insulin Degludec58$23,519
Repatha SyringeEvolocumab20$21,316
MounjaroTirzepatide12$19,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,284
Humalog Kwikpen U-200Insulin Lispro34$14,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$30$467,600420 claims
Novo NordiskOzempic$26$249,137206 claims
MerckJanuvia, Janumet, Janumet Xr$37$242,532247 claims
GSKBreo Ellipta, Trelegy Ellipta$128$82,751139 claims
AstraZenecaFarxiga, Symbicort$71$53,64382 claims
NovartisEntresto$43$51,03346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →